Trial Profile
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Sym-022 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Symphogen
- 21 Sep 2020 Results of three phase1, first-in-human studies (NCT03311412, NCT03489369; NCT03489343) assessing effect Sym021, Sym022, and Sym023 alone and Sym021 in combination with either Sym022 or Sym023, presented at the 45th European Society for Medical Oncology Congress.
- 27 Mar 2020 Status changed from active, no longer recruiting to completed.
- 02 Jan 2020 Status changed from recruiting to active, no longer recruiting.